Sonrotoclax monotherapy produced durable responses in Chinese patients with relapsed/refractory mantle cell lymphoma.
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
2
pTVG-HP DNA Vaccine Extends Overall Survival vs Placebo in PSA-Recurrent Prostate Cancer
3
FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC
4
China’s NMPA Accepts NDA for Opamtistomig in Pretreated Advanced Extrapulmonary NEC
5